about
Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcriptionThe role of oxidative stress in Parkinson's diseaseParkin accumulation in aggresomes due to proteasome impairmentMitochondrial localization of DJ-1 leads to enhanced neuroprotectionStriatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movementsPQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domainPQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survivalCasein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formationEffect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's diseaseDopamine receptor regulating factor, DRRF: a zinc finger transcription factorDJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex.MicroRNAs in Parkinson's disease.Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.Advances in gene therapy for movement disorders.Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice.MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse modelMicroRNAs in neurodegenerative diseases and their therapeutic potential.Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.Characterization of a corticotropin releasing hormone responsive region in the murine proopiomelanocortin gene.Interaction of nuclear factors from young and old rat brain regions with regulatory sequences of the D2 dopamine receptor gene promoter.Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone.Up-regulation of D1A dopamine receptor gene transcription by estrogen.In vivo regulation of glial cell line-derived neurotrophic factor-inducible transcription factor by kainic acid.Neural cell line-specific regulatory DNA cassettes harboring the murine D1A dopamine receptor promoter.Two distinct promoters drive transcription of the human D1A dopamine receptor gene.Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating factor).Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies.Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear palsy.Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.Alternate 5' exons in the rat brain-derived neurotrophic factor gene: differential patterns of expression across brain regions.Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.Regulation of striatal dopamine receptors by corticosterone: an in vivo and in vitro study.Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.MicroRNAs in neurodegenerative disorders.Modulation of nigrostriatal dopaminergic transmission by antisense oligodeoxynucleotide against brain-derived neurotrophic factor.
P50
Q22253891-A3DBA724-C793-4C40-8B92-9D0B510937A0Q24307946-9049F6E2-9D7E-44AA-9CDC-A5F30D8B4626Q24308757-866C3677-185D-4791-AD6F-5DFAD2220E8DQ24324226-EA60506F-0CB6-4677-8922-8A1D7EDF07E6Q24632752-F7DEA143-F616-43A7-9A2E-19F3CE4A3445Q28139548-E1904AE1-21A2-460C-ACA8-28299B7DDC84Q28144288-6B1F78F7-291D-4BA5-B834-7B87E4FEA80AQ28188133-5D149923-2410-4106-A280-75AC68A165FAQ28284091-5B052F34-9389-4B3E-B130-34EF34704D4DQ28589191-80740B8E-A2C9-487B-9B2F-4FAB6028C86DQ33905966-33AF266C-4474-48D5-8BA1-12886F2EB10CQ34247027-C01437B3-AE1E-4D02-B0D3-F063F9BA11ADQ34406533-55D79E5F-27BB-4490-8790-C9144673E8C9Q34656049-716D8B65-24EB-4931-AFF0-73F6F230049CQ34717871-F39E3A65-A166-4CE2-88C5-1DCFF087482FQ34980198-B33B48B9-A335-44CE-9377-8F7FEE87383EQ37289669-2EC6B900-5BDE-459F-926D-8F28F69F1FB7Q37946984-D37D627D-3B7E-42C7-B28F-E17CCEB8376AQ37972777-8FE6F061-0891-4A00-9D13-FB62C918537AQ38314854-AB88B953-E8DE-45EF-A7D6-1567103B852EQ38348887-6F050071-7E88-4CFF-A91A-D778FA8C904FQ39853599-F08ADE0C-62BF-4EF0-95EF-86BC180DFE4BQ40909896-5F05ABC8-B02C-4124-96D6-DC11C05491D3Q40915260-0D06D067-44EA-4740-9282-2A702CB471E6Q40915626-C4642FE8-9692-478C-AFC3-A8B171D2D039Q41159199-39DD97D3-8F1C-491F-A2AC-B4B26891EECBQ41450662-7C9DF963-C9E1-4F9E-AC05-451F674595C4Q41509268-345DDD7F-B2E9-4820-8C58-F81CCF18539AQ42555197-7EDCA249-B443-4829-B7A7-AEC23C886758Q43629208-2CB9D096-6CDE-4B35-959E-5728E73DFA1EQ43823673-31D277B3-6D93-4851-B0E4-5BF48B24687CQ44529077-34121C8C-3A43-4BD7-B8EE-4862A6129AC5Q45295474-6E8FA904-500F-4605-9B4D-542E342F32B1Q45711545-1F43F2DE-DA69-485E-AEF1-A98270ECA539Q48078800-053E721B-F3D2-4A70-95C3-54D898C0031CQ48093936-88030BFD-A5D4-482A-A546-B372BA1D4C79Q48188018-EF18579C-E380-4CA1-A90B-56F80F897945Q48188336-5F87B5A3-1813-432B-A5DE-763916113E8CQ48231030-0467C6C1-F7A9-4A5A-AE13-24ADFE43F65BQ48480077-40A40DE9-A942-4919-BDF1-EA9C3638DCB3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M. Maral Mouradian
@ast
M. Maral Mouradian
@en
M. Maral Mouradian
@es
M. Maral Mouradian
@nl
type
label
M. Maral Mouradian
@ast
M. Maral Mouradian
@en
M. Maral Mouradian
@es
M. Maral Mouradian
@nl
altLabel
M M Mouradian
@en
Mouradian MM
@en
prefLabel
M. Maral Mouradian
@ast
M. Maral Mouradian
@en
M. Maral Mouradian
@es
M. Maral Mouradian
@nl
P106
P1153
7005678805
P31
P4012
P496
0000-0002-9937-412X